Litigation

Search documents
Shareholder Alert: Robbins LLP Informs Investors of the Vestis Corporation Class Action
Prnewswire· 2025-06-10 01:14
Core Viewpoint - A class action lawsuit has been filed against Vestis Corporation for allegedly misleading investors about customer growth and strategic initiatives [1][2]. Allegations - The complaint claims that Vestis Corporation did not disclose its inability to execute planned strategic initiatives aimed at improving customer experience and onboarding, which were expected to drive new customer growth and retention [2]. - It is alleged that these misleading statements led to investors purchasing Vestis securities at artificially inflated prices [2]. Financial Results and Market Reaction - On May 7, 2025, Vestis announced disappointing financial results for Q2 of fiscal 2025, withdrew its revenue guidance for the full year, and provided third-quarter guidance that was significantly below market expectations [3]. - The company attributed its poor performance to "lost business in excess of new business" and "lower adds over stops," indicating a decline in volume changes with existing customers [3]. - Following this announcement, Vestis' stock price plummeted from $8.71 per share on May 6, 2025, to $5.44 per share on May 7, 2025, marking a decline of approximately 37.54% in just one day [3]. Class Action Participation - Shareholders interested in participating in the class action must file a motion for lead plaintiff by August 8, 2025, with the lead plaintiff representing other class members in the litigation [4]. - Shareholders can choose to remain absent from the case while still being eligible for recovery [4]. Company Background - Robbins LLP, the firm leading the class action, specializes in shareholder rights litigation and has been active in helping shareholders recover losses and improve corporate governance since 2002 [5].
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Red Cat and Fortrea and Encourages Investors to Contact the Firm
GlobeNewswire News Room· 2025-06-10 01:00
Red Cat Holdings, Inc. (NASDAQ: RCAT) - Class action lawsuit initiated for stockholders covering the period from March 18, 2022, to January 15, 2025, with a lead plaintiff deadline of July 22, 2025 [2] - Allegations include misleading statements regarding the production capacity of Red Cat's Salt Lake City facility and the value of the Short Range Reconnaissance Program contract [3][4] - On July 27, 2023, Red Cat disclosed that its facility could only produce 100 drones per month, leading to a nearly 9% drop in stock price [4] - Financial results for Q1 FY2025 revealed losses per share of $0.17, missing estimates by $0.09, and revenue of $2.8 million, missing by $1.07 million, causing a more than 25% decline in stock price [5] - A report from Kerrisdale Capital on January 16, 2025, claimed the SRR contract was less favorable than previously indicated, resulting in a stock price drop of over 21% [6] Fortrea Holdings Inc. (NASDAQ: FTRE) - Class action lawsuit initiated for stockholders covering the period from July 3, 2023, to February 28, 2025, with a lead plaintiff deadline of August 1, 2025 [7] - Fortrea was spun off from Labcorp Holdings Inc. in June 2023, and entered into transition services agreements with Labcorp [7] - On March 3, 2025, Fortrea announced that its revenue and adjusted EBITDA expectations for 2025 were not aligned with prior forecasts, leading to a stock price drop of 25.05% [8] - Allegations include overestimating revenue from Pre-Spin projects and overstating cost savings from exiting TSAs, which inflated EBITDA targets and overstated the viability of the post-Spin-Off business model [9]
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of Vestis Corporation Securities and Sets a Lead Plaintiff Deadline of August 8, 2025
GlobeNewswire News Room· 2025-06-09 20:41
NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Vestis Corporation (“Vestis” or the “Company”) (NYSE: VSTS) between May 2, 2024, to May 6, 2025, both dates inclusive. You are hereby notified that the class action lawsuit Cesar Torres v. Vestis Corporation, et al. (Case No. 1:25-cv-04844) has been commenced in the United States District Court for the Southern District of ...
INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that DoubleVerify Holdings, Inc. (DV) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
GlobeNewswire News Room· 2025-06-09 13:30
SAN DIEGO, June 09, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of DoubleVerify Holdings, Inc. (NYSE: DV) common stock between November 10, 2023 and February 27, 2025, all dates inclusive (the “Class Period”), have until July 21, 2025 to seek appointment as lead plaintiff of the DoubleVerify class action lawsuit. Captioned Electrical Workers Pension Fund, Local 103, I.B.E.W. v. DoubleVerify Holdings, Inc., No. 25-cv-04332 (S.D.N.Y.), the DoubleVerify cla ...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NWTN Inc. - NWTN
Prnewswire· 2025-06-07 14:00
NEW YORK, June 7, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of NWTN Inc. ("NWTN" or the "Company") (NASDAQ: NWTN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.The investigation concerns whether NWTN and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action]On May 28, 2025, NWTN disclosed receipt ...
OGN INVESTOR NOTICE: Organon & Co. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
Prnewswire· 2025-06-07 02:45
Core Viewpoint - The Organon class action lawsuit alleges that the company and its executives made misleading statements regarding capital allocation and dividend payouts, leading to significant financial losses for investors [1][4][5]. Group 1: Lawsuit Details - The lawsuit, titled Hauser v. Organon & Co., seeks to represent purchasers of Organon securities and claims violations of the Securities Exchange Act of 1934 [1]. - Allegations include the concealment of material information about Organon's capital allocation priorities and a drastic reduction of the quarterly dividend payout by over 70% [4]. - On May 1, 2025, Organon announced a reduction in its dividend payout from $0.28 to $0.02, resulting in a stock price drop of more than 27% [5]. Group 2: Legal Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Organon securities during the class period to seek appointment as lead plaintiff [6]. - The lead plaintiff represents the interests of all class members and can select a law firm for litigation [6]. Group 3: Company Background - Organon develops health solutions through prescription therapies and medical devices [3]. - Robbins Geller Rudman & Dowd LLP, the law firm handling the case, is recognized for its success in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 [7].
RBGLY Investor Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Against Reckitt Benckiser Group PLC
GlobeNewswire News Room· 2025-06-06 22:12
Core Viewpoint - Robbins LLP has initiated a class action lawsuit on behalf of investors who acquired Reckitt Benckiser Group PLC American Depository Shares (ADSs) between January 13, 2021, and July 28, 2024, alleging that the company misled investors regarding the safety of its Enfamil baby formula [1][2]. Allegations - The lawsuit claims that Reckitt failed to inform investors and consumers about the increased risk of necrotizing enterocolitis (NEC) in preterm infants consuming its cow's milk-based formula, Enfamil, and the potential negative impact on sales and legal exposure [2]. - A jury in Illinois awarded $60 million in a case against Mead Johnson, finding negligence in failing to warn about the risks associated with cow's milk-based formula, which led to a significant drop in Reckitt's ADS price [3]. - Following a similar case in Missouri, where Abbott Laboratories was found liable for NEC-related damages, Reckitt's ADS price also experienced a notable decline [4]. Class Action Participation - Shareholders interested in serving as lead plaintiffs in the class action must file a motion by August 4, 2025, but participation is not required to be eligible for recovery [5].
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Arvinas, Inc. - ARVN
GlobeNewswire News Room· 2025-06-06 16:20
Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Arvinas, Inc. and its officers or directors [1] Company Developments - On May 1, 2025, Arvinas announced the removal of plans for a Phase 3 first-line combination trial with atirmociclib and a Phase 3 second-line combination trial with a CDK4/6 inhibitor from its joint development plan with Pfizer [3] - The decision to remove these trials was based on a review of emerging information, external data results, the evolving treatment landscape in metastatic breast cancer, and long-term capital allocation [3] - Arvinas also announced a workforce reduction of approximately one-third to streamline operations and enable efficient progression of its portfolio, with completion planned for the second quarter of 2025 [3] - Following this news, Arvinas's stock price fell by $2.39 per share, or 24.84%, closing at $7.23 per share on May 1, 2025 [3]
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Red Cat Holdings
GlobeNewswire News Room· 2025-06-06 15:02
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Red Cat To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Red Cat between March 18, 2022 and January 15, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Faruqi ...
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Treace Medical
GlobeNewswire News Room· 2025-06-06 14:20
Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Treace Medical Concepts, Inc. due to allegations of misleading statements and failure to disclose important information regarding competition and revenue guidance [3][5]. Group 1: Allegations Against Treace Medical - The complaint alleges that Treace Medical and its executives violated federal securities laws by making false and misleading statements [5]. - Key issues include the impact of competition on the demand for Treace's primary product, the Lapiplasty 3D Bunion Correction System, leading to a decline in revenue [5]. - The company had to accelerate plans for an alternative product to osteotomy due to competitive pressures [5]. Group 2: Revenue Guidance and Stock Impact - On May 7, 2024, Treace Medical lowered its full-year 2024 revenue guidance from $220 million-$225 million to $201 million-$211 million [6]. - Following this announcement, the company's stock price fell by $6.95, or nearly 63%, closing at $4.17 per share on May 8, 2024, with unusually high trading volume [7]. Group 3: Legal Proceedings and Class Action - Investors who suffered losses are encouraged to contact Faruqi & Faruqi to discuss their legal rights and options [1][9]. - There is a June 10, 2025 deadline for investors to seek the role of lead plaintiff in the federal securities class action against Treace Medical [3].